Abstract
Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 56-59 |
Number of pages | 4 |
Journal | Experimental and Clinical Endocrinology and Diabetes |
Volume | 109 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2001 |
Keywords
- Gene therapy
- Prostate cancer
- Sodium/iodide symporter (NIS)
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology